Munich - Delayed Quote EUR

Nanobiotix SA (5NRA.MU)

Compare
3.2400 0.0000 (0.00%)
At close: December 23 at 8:18:24 AM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 5NRA.MU

Recent News: 5NRA.MU

View More
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
GlobeNewswire 8 days ago
Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company
GlobeNewswire 14 days ago
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
GlobeNewswire 16 days ago
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
GlobeNewswire last month
NANOBIOTIX to Participate in Multiple Investor Conferences in November

NANOBIOTIX to Participate in Multiple Investor Conferences in November
GlobeNewswire last month
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
GlobeNewswire 3 months ago
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
GlobeNewswire 3 months ago
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire 3 months ago
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
GlobeNewswire 6 months ago
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
GlobeNewswire 6 months ago
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
GlobeNewswire 6 months ago
View More